International Anal Neoplasia Society Scientific Meeting Amsterdam 2019

International Anal Neoplasia Society Scientific Meeting Amsterdam 2019 

Danni and Sarah from the mASCARA team are attending the IANS Scientific Meeting  in Amsterdam in November. The programme looks excellent, in particular we are looking forward to the updates on the SPANC and ANCHOR trials. 

We are also looking forward to making further mASCARA collaborations. If you are attending and would like to discuss mASCARA with us we will be delighted to meet you! Tweet us! @mascararegistry  

mASCARA team in Vienna!

Members of the mASCARA team are attending the European Society of Coloproctology Conference later this month in Vienna where we will be presenting our work on Anal Intraepithelial Neoplasia topical and ablative treatments.  

We are looking to make further collaborations for mASCARA, so if you have a passion for research into Anal SCC or AIN we would love to meet you! @mascararegistry 

Increases in Anal SCC incidence in England

The mASCARA team is very interested to learn from Public Health England that the incidence of Anal SCC in England has increased by 23% from 2013-2017 with female incidence increasing more rapidly than male incidence (29% compared to 14%).  This increasing trend has been identified all over the world. We hope that mASCARA will be able to help identify whether this is due to a change in patient demographics (such as more patients having immunosuppressive co-morbidities such as HIV) or if this is related to other factors.  

We’d love to hear your opinions! Tweet us! @mascararegistry 

mASCARA recruitment has begun

We are excited to announce that clinical center site recruitment has begin for mASCARA. We would love to collaborate with other research centers with an interest in being included in the first multinational Anal Squamous Cell Carcinoma data collaboration.

If you are interested in taking part – please tweet us @mascararegistry or contact us though the website contact from. We are looking forward to working with you.


The mASCARA study team from Imperial College London and Chelsea and Westminster Hospital NHS Foundation Trust had a great time at ESCP this year. Great Collaborations made. Looking forward to working together on this project!.

Dinner out with Colleagues

Team mASCARA in Nice

Our mASCARA study team will be at the European Society of Coloprotoctology Conference next month in Nice. It would be great to catch up with other like minded Colorectal Units with an interest in Anal Squamous Cell Carcinoma.


After discussions with study members at Imperial College London and our primary clinical site Chelsea and Westminster Hospital NHS Foundation Trust we have agreed that our study name should be:

Multinational Anal Squamous Cell Carcinoma Registry and Audit.

Aerial View of Imperial College London South Kensington Campus

We are now in the process of getting Ethics approval and consulting with GDPR experts at Imperial College London.


EU General Data Protection Regulation is coming into force today. Thanks to Imperial College London for their help in setting up what will be the first GDPR compliant cancer registry at Imperial.

Why are creating an International Database?

Anal Squamous Cell Carcinoma (ASCC) is an uncommon cancer with an incidence rate between 1 and 2 per 100000 per year. However, the incidence of ASCC is increasing rapidly, with up to 6.8% increase in men per year and 10.7% increase in women per year since 1971.

It is believed that the increasing numbers of HIV positive patients who are living longer on advanced antiretrovirals are likely to be contributing to the increasing burden of ASCC.

Anal Intraepithelial Neoplasia (AIN) is the known precursor to ASCC. It is believed that by identifying and treating high grade AIN that ASCC could become a preventable cancer. ASCC also has excellent outcomes if identified early. Only 15% of ASCC present with metastasis and most patients are diagnosed with resectable T1 tumours. However, current guidelines are conflicting and not based on good quality clinical evidence,

The limiting factor to providing good quality evidence is the large samples size required to observe the relationship between AIN transformation and ASCC. This is yet to be achieved.

In response to this ongoing issue, we are developing an Anal Squamous Cell Carcinoma Registry to allow collaboration between international clinical communities.